G Curigliano1, G Viale2, M Ghioni2, A A Jungbluth3, V Bagnardi4, G C Spagnoli5, A M Neville6, F Nolè7, N Rotmensz8, A Goldhirsch7. 1. Department of Medicine, Division of Medical Oncology. Electronic address: giuseppe.curigliano@ieo.it. 2. Division of Pathology, Istituto Europeo di Oncologia; University of Milan School of Medicine, Milano, Italy. 3. Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan-Kettering Cancer Center, New York, NY, USA. 4. Division of Epidemiology and Biostatistics, Istituto Europeo di Oncologia; Department of Statistics, University of Milan Bicocca, Milano, Italy. 5. Institute of Surgical Research and Hospital Management, University Hospital Basel, Switzerland. 6. Ludwig Institute for Cancer Research, New York, NY, USA. 7. Department of Medicine, Division of Medical Oncology. 8. Division of Epidemiology and Biostatistics, Istituto Europeo di Oncologia.
Abstract
BACKGROUND: cancer-testis (CT) antigens, frequently expressed in human germline cells but not in somatic tissues, may become aberrantly reexpressed in different cancer types. The aim of this study was to investigate the expression of CT antigens in breast cancer. PATIENTS AND METHODS: a total of 100 selected invasive breast cancers, including 50 estrogen receptor (ER) positive/HER2 negative and 50 triple negative (TN), were examined for NY-ESO-1 and MAGE-A expression by immunohistochemistry. RESULTS: a significantly higher expression of MAGE-A and NY-ESO-1 was detected in TN breast cancers compared with ER-positive tumors (P = 0.04). MAGE-A expression was detected in 13 (26%) TN cancers compared with 5 (10%) ER-positive tumors (P = 0.07). NY-ESO-1 expression was confirmed in nine (18%) TN tumor samples compared with two (4%) ER-positive tumors. CONCLUSIONS: MAGE-A and NY-ESO-1 CT antigens are expressed in a substantial proportion of TN breast cancers. Because of the limited therapeutic options for this group of patients, CT antigen-based vaccines might prove to be useful for patients with this phenotype of breast cancer.
BACKGROUND:cancer-testis (CT) antigens, frequently expressed in human germline cells but not in somatic tissues, may become aberrantly reexpressed in different cancer types. The aim of this study was to investigate the expression of CT antigens in breast cancer. PATIENTS AND METHODS: a total of 100 selected invasive breast cancers, including 50 estrogen receptor (ER) positive/HER2 negative and 50 triple negative (TN), were examined for NY-ESO-1 and MAGE-A expression by immunohistochemistry. RESULTS: a significantly higher expression of MAGE-A and NY-ESO-1 was detected in TN breast cancers compared with ER-positive tumors (P = 0.04). MAGE-A expression was detected in 13 (26%) TN cancers compared with 5 (10%) ER-positive tumors (P = 0.07). NY-ESO-1 expression was confirmed in nine (18%) TN tumor samples compared with two (4%) ER-positive tumors. CONCLUSIONS: MAGE-A and NY-ESO-1 CT antigens are expressed in a substantial proportion of TN breast cancers. Because of the limited therapeutic options for this group of patients, CT antigen-based vaccines might prove to be useful for patients with this phenotype of breast cancer.
Authors: Christoph Domschke; Andreas Schneeweiss; Stefan Stefanovic; Markus Wallwiener; Joerg Heil; Joachim Rom; Christof Sohn; Philipp Beckhove; Florian Schuetz Journal: Breast Care (Basel) Date: 2016-04-27 Impact factor: 2.860
Authors: Richard A Morgan; Nachimuthu Chinnasamy; Daniel Abate-Daga; Alena Gros; Paul F Robbins; Zhili Zheng; Mark E Dudley; Steven A Feldman; James C Yang; Richard M Sherry; Giao Q Phan; Marybeth S Hughes; Udai S Kammula; Akemi D Miller; Crystal J Hessman; Ashley A Stewart; Nicholas P Restifo; Martha M Quezado; Meghna Alimchandani; Avi Z Rosenberg; Avindra Nath; Tongguang Wang; Bibiana Bielekova; Simone C Wuest; Nirmala Akula; Francis J McMahon; Susanne Wilde; Barbara Mosetter; Dolores J Schendel; Carolyn M Laurencot; Steven A Rosenberg Journal: J Immunother Date: 2013-02 Impact factor: 4.456